Judge to Approve Purdue Pharma Settlement in Landmark Opioid Case

A federal bankruptcy court judge announced Friday his intention to approve OxyContin-maker Purdue Pharma’s latest settlement plan, marking a potential conclusion to one of the most complex bankruptcy cases in U.S. history. The agreement requires members of the Sackler family, who own the company, to contribute up to $7 billion over 15 years to resolve thousands of lawsuits related to the nation’s devastating opioid epidemic.

Judge Sean Lane indicated he would formally explain his decision during a hearing scheduled for Tuesday. This revised agreement replaces an earlier settlement plan that the U.S. Supreme Court rejected last year on the grounds it improperly shielded Sackler family members from future litigation.

The settlement represents one of the largest among numerous agreements reached between government entities and companies in the pharmaceutical supply chain, including drugmakers, wholesalers, and pharmacies. It could effectively close a protracted legal battle over Purdue’s role in an opioid crisis linked to approximately 900,000 deaths in the United States since 1999.

“The plan is entirely lawful, does the greatest good for the greatest number in the shortest available timeframe,” said Marshall Huebner, Purdue’s attorney, during court proceedings. He acknowledged the impossibility of fully compensating those affected, stating he wished he could “conjure up $40 trillion or $100 trillion to compensate those who have suffered unfathomable loss.”

The bankruptcy case, which began six years ago when Purdue sought protection from lawsuits with claims that eventually grew to trillions of dollars, has been described by legal professionals as one of the most complicated bankruptcy proceedings in American history. The final agreement garnered near-unanimous support from attorneys representing various stakeholders, including Purdue, government entities, Native American tribes, and individuals affected by addiction.

The revised settlement addresses the Supreme Court’s concerns by allowing entities that do not opt into the settlement to pursue legal action against Sackler family members. However, legal experts note that much of the family’s wealth is held in trusts in offshore accounts, making it difficult to access through lawsuits despite their collective worth of billions.

Unlike the previous proposal, this settlement has faced significantly less opposition. Out of more than 54,000 personal injury victims who voted on the plan, only 218 voted against it, though many eligible voters did not participate. The hearings proceeded without the protests that characterized earlier proceedings, though some objectors did speak during the three-day hearing, occasionally interrupting the judge.

Some critics argued that only victims, not government entities, should receive settlement funds. Others pressed for criminal liability for Sackler family members, which Judge Lane clarified was beyond the bankruptcy court’s jurisdiction, though the settlement does not prevent prosecutors from pursuing such cases.

The settlement includes several key provisions beyond the financial contributions. The Sackler family will formally relinquish ownership of Purdue Pharma, which will be renamed Knoa Pharma and placed under new management dedicated to using future profits to combat the opioid crisis. This transition could occur by spring 2026.

Family members will be barred from involvement in companies selling opioids worldwide and prohibited from having their names added to institutions in exchange for charitable contributions. Many institutions have already removed the Sackler name from buildings and programs. Additionally, company documents, including those normally protected by attorney-client privilege, will be made public.

Notably, this settlement differs from other major opioid agreements by allocating approximately $850 million directly to individuals harmed by Purdue’s products. About $100 million of this amount is designated specifically to help children born with opioid withdrawal. All payments to individual victims are scheduled for distribution next year.

Among the approximately 139,000 people with active claims, those who can demonstrate they were prescribed Purdue opioids for at least six months may receive about $16,000 each, while those with shorter prescription periods could receive around $8,000, before legal fees.

Some victims’ advocates criticized the settlement amount as insufficient. During Thursday’s proceedings, Laureen Ferrante of Staten Island, New York, questioned how officials could “sleep at night knowing people are going to get so little money they can’t do anything with it.” However, Christopher Shore, representing individual victims, argued that the settlement offers better prospects than pursuing litigation against Sackler family members, noting that “sometimes bad people win in litigation.”

The majority of settlement funds will go to state and local governments to support opioid crisis mitigation efforts. Experts believe such settlement dollars have already contributed to recent declines in overdose death rates across the country.